Compare IDYA & BTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDYA | BTX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 773.8M |
| IPO Year | 2019 | N/A |
| Metric | IDYA | BTX |
|---|---|---|
| Price | $34.04 | $6.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $49.42 | N/A |
| AVG Volume (30 Days) | 913.9K | ★ 930.0K |
| Earning Date | 11-04-2025 | 11-01-2025 |
| Dividend Yield | N/A | ★ 14.13% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $214,834,000.00 | N/A |
| Revenue This Year | $2,434.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5377.66 | N/A |
| 52 Week Low | $13.45 | $5.10 |
| 52 Week High | $37.08 | $8.31 |
| Indicator | IDYA | BTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.27 | 43.76 |
| Support Level | $33.12 | $6.66 |
| Resistance Level | $37.08 | $6.84 |
| Average True Range (ATR) | 1.45 | 0.12 |
| MACD | -0.31 | 0.01 |
| Stochastic Oscillator | 24.75 | 48.58 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.